LEVEL 4 R03DX05

Δραστικές

Φάρμακα

  • DRUGBANK - Omalizumab
  • indication:

    For treatment of asthma caused by allergies

  • pharmacology:

  • mechanism:

    Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.

  • toxicity:

  • absorprion:

  • halflife:

    26 days

  • roouteelimination:

    Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.

  • volumedistribution:

    * 78 ± 32 mL/kg

  • clearance: